$LNSR News
Last published 1d ago
- 1d agoLNSRLENSAR Inc. Third Quarter 2026 Results Conference Call - LENSAR INCEarnings Call TranscriptsGood morning and thank you for your participation. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. If you would like to ask a question during this time simp
- 1d agoLNSRLENSAR, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoLNSRLENSAR® Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire10 ALLY Robotic Cataract Laser Systems ® (“ALLY System”) Placements in Third Quarter 2026; Backlog of 12 ALLY Systems as of September 30, 2026
- 1w agoLNSRLENSAR® to Report Third Quarter 2026 Results on November 10th, 2026GlobeNewswireORLANDO, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the
- 3mo agoLNSRLENSAR Inc. Second Quarter 2026 Results Conference Call - LENSAR INCEarnings Call TranscriptsHello, and welcome to Lensar, Inc. Second Quarter 2026 Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To
- 3mo agoLNSRLENSAR® Reports Second Quarter 2026 Results and Provides Business UpdateGlobeNewswire10 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser
- 3mo agoLNSRLENSAR® to Report Second Quarter 2026 Results on August 13th, 2026GlobeNewswireORLANDO, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the
- 6mo agoLNSRLENSAR Inc. First Quarter 2026 Results Conference CallLENSAR INCEarnings Call TranscriptsThank you for standing by. Welcome to the LENZAR first quarter 2026 results conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer s
- 6mo agoLNSRLENSAR® Reports First Quarter 2026 Results and Provides Business UpdateGlobeNewswire7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base
- 6mo agoLNSRLENSAR® to Report First Quarter 2026 Results on May 8, 2026GlobeNewswireORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts,
- 7mo agoLNSRLENSAR Inc. Fourth Quarter 2025 Results Conference CallLENSAR INCEarnings Call TranscriptsGood morning and thank you for your participation. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. To ask a question, please press star 1-1 on your telephon
- 7mo agoLNSRLENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business UpdateGlobeNewswire15 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13%
- 8mo agoALCLNSRAlcon and LENSAR, Inc. Agree to Terminate Merger AgreementBusiness WireAlcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies'
- 8mo agoLNSRLENSAR® Announces Termination of Merger Agreement with Alcon Research, LLCGlobeNewswireORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts,
- 8mo agoLNSRLENSAR® Provides Update on Pending Acquisition by AlconGlobeNewswireORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts,
- 1y agoLNSRLENSAR® Reports Third Quarter 2025 Results and Provides Business UpdateGlobeNewswire18 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew
- 1y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three
- 1y agoGERNGMABLNSRSpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of DirectorsGlobeNewswireALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of
- 1y agoLNSRLENSAR Reports Second Quarter 2025 Results and Provides Business UpdateGlobeNewswire18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed
- 1y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three
- 1y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted 10 newly-hired
- 1y agoLNSRLENSAR Reports First Quarter 2025 Results and Provides Business UpdateGlobeNewswire14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter
- 1y agoALCLNSRAlcon Agrees to Acquire LENSAR, Inc.GlobeNewswireAcquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolioNext generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA
- 1y agoALCLNSRAlcon Agrees to Acquire LENSAR, Inc.Business WireAcquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency of cataract
- 1y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired
- 1y agoLNSRLENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateGlobeNewswire31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of
- 1y agoLNSRLENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025GlobeNewswireORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts,
- 1y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireORLANDO, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired
- 1y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three
- 1y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireORLANDO, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted four newly-hired
- 1y agoLNSRLENSAR to Participate in the BTIG 4th Annual Ophthalmology DayGlobeNewswireORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts,
- 2y agoLNSRLENSAR, Inc. (LNSR) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLNSRLENSAR Reports Third Quarter 2024 Results and Provides Business UpdateGlobeNewswire24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over
- 2y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireORLANDO, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired
- 2y agoLNSRLENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024GlobeNewswireORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts,
- 2y agoLNSROne Millionth Procedure Completed Using LENSAR's Cataract Laser SystemsGlobeNewswireORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts,
- 2y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired
- 2y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireLENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to
- 2y agoLNSRLENSAR to Participate in Two Upcoming Investor ConferencesBusiness WireLENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that management will participate in
- 2y agoLNSRLENSAR, Inc. (LNSR) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLNSRLENSAR Reports Second Quarter 2024 Results and Provides Business UpdateBusiness Wire17 New ALLY® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval granted for
- 2y agoLNSRLENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European UnionBusiness WireFirst EU ALLY Commercial Installation Planned for August 2024 LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of
- 2y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireLENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to
- 2y agoLNSRLENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024Business WireLENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the Company's second quarter 2024
- 2y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireLENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to
- 2y agoLNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireLENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to
- 2y agoLNSRLENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads ConferenceBusiness WireLENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that Nick Curtis, Chief
- 2y agoLNSRLENSAR, Inc. (LNSR) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLNSRLENSAR Reports First Quarter 2024 Results and Provides Business UpdateBusiness WireTotal Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY® Adaptive Cataract Treatment System installed base to 65 systems LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR"
- 2y agoLNSRLENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024Business WireLENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's first